HTA Submission Support (NICE, HAS, AMNOG)
Helping Life Sciences Companies Achieve Faster Reimbursement and Market Access
Obtaining regulatory approval is a major milestone in the development of a pharmaceutical product or medical technology, but it is no longer sufficient to guarantee commercial success. Across Europe and many global healthcare markets, manufacturers must also demonstrate that their products provide meaningful clinical and economic value compared with existing standards of care. Health Technology Assessment (HTA) has therefore become a critical step in securing reimbursement, pricing approvals, and patient access.
Health Technology Assessment organizations evaluate whether new medicines, biologics, medical devices, diagnostics, and advanced therapies deliver sufficient value to justify reimbursement within national healthcare systems. These evaluations influence pricing negotiations, reimbursement decisions, formulary placement, treatment guidelines, and ultimately the commercial success of innovative therapies.
As healthcare budgets become increasingly constrained and evidence expectations continue to evolve, pharmaceutical and biotechnology companies require comprehensive market access strategies supported by robust clinical evidence, health economics, real-world data, and compelling value communication.
At BioNetwork Consulting, our HTA Submission Support (NICE, HAS & AMNOG) Services help pharmaceutical companies, biotechnology organizations, and medical device manufacturers prepare high-quality Health Technology Assessment submissions that maximize reimbursement opportunities, accelerate market access, and support successful commercialization across Europe and other international markets.
Accelerating Market Access Through Successful HTA Submissions
Health Technology Assessment has become one of the most influential components of pharmaceutical commercialization. While regulatory agencies evaluate safety, quality, and efficacy, HTA bodies focus on comparative clinical value, cost-effectiveness, patient outcomes, healthcare resource utilization, and long-term economic impact.
Positive HTA decisions enable companies to secure reimbursement, negotiate pricing with national healthcare systems, gain favorable formulary positioning, and expand patient access. Conversely, insufficient evidence or poorly prepared submissions can delay reimbursement, reduce pricing flexibility, or limit market adoption.
BioNetwork Consulting helps organizations integrate market access planning early in product development, ensuring evidence generation strategies align with future HTA expectations. By considering payer requirements during clinical development rather than after regulatory approval, companies significantly improve the likelihood of successful reimbursement outcomes.
Navigating NICE, HAS, AMNOG and EU Joint HTA Requirements
Each Health Technology Assessment authority applies unique evaluation methodologies, evidence requirements, and reimbursement processes.
The National Institute for Health and Care Excellence (NICE) in the United Kingdom evaluates clinical effectiveness, cost-effectiveness, and overall value for the National Health Service (NHS). NICE submissions require robust economic modeling, comparative clinical evidence, quality-adjusted life year (QALY) analyses, and comprehensive value demonstrations.
France’s Haute Autorité de Santé (HAS) assesses clinical benefit (Service Médical Rendu) and improvement in clinical benefit (Amélioration du Service Médical Rendu), influencing pricing and reimbursement decisions through evidence-based evaluations.
Germany’s AMNOG framework requires manufacturers to demonstrate additional therapeutic benefit compared with the established standard of care. These assessments influence reimbursement negotiations and long-term commercial positioning within the German healthcare system.
Our Health Technology Assessment Consulting Services
BioNetwork Consulting provides end-to-end consulting services covering every stage of Health Technology Assessment preparation and market access planning.
We assist organizations with HTA strategy development, evidence gap assessments, payer landscape analysis, comparator selection, clinical evidence synthesis, systematic literature reviews, indirect treatment comparisons, network meta-analyses, health economic modeling, budget impact analyses, value dossier development, reimbursement strategy, stakeholder engagement, submission planning, and lifecycle evidence generation.
Our consultants collaborate closely with clinical development, regulatory affairs, medical affairs, HEOR, commercial, and market access teams to ensure evidence generation activities support both regulatory approvals and reimbursement objectives.
Clinical Evidence, HEOR and Value Dossier Development
Successful HTA submissions rely on compelling evidence that demonstrates meaningful clinical value and economic benefit.
BioNetwork Consulting supports the development of comprehensive evidence packages by integrating clinical trial data, real-world evidence (RWE), Health Economics and Outcomes Research (HEOR), patient-reported outcomes, epidemiology, treatment pathway analyses, and comparative effectiveness research.
Our consultants prepare value dossiers that clearly communicate the product’s clinical differentiation, economic impact, patient benefits, healthcare resource utilization, and long-term value proposition.
We also develop cost-effectiveness models, budget impact analyses, scenario analyses, sensitivity testing, and payer-focused communication materials that strengthen reimbursement negotiations.
Frequently Asked Questions
Health Technology Assessment is the systematic evaluation of the clinical effectiveness, economic value, safety, and broader impact of healthcare technologies to support reimbursement and pricing decisions.
BioNetwork Consulting supports submissions to NICE (United Kingdom), HAS (France), AMNOG (Germany), and organizations operating under the EU Joint HTA Regulation, along with other international HTA bodies.
Our services include HTA strategy development, clinical evidence synthesis, HEOR, health economic modeling, value dossier preparation, reimbursement strategy, payer evidence generation, comparative effectiveness analysis, and submission planning.
Regulatory authorities evaluate safety, quality, and efficacy for product approval, whereas HTA agencies assess clinical value and cost-effectiveness to determine reimbursement and pricing.
Pharmaceutical companies, biotechnology firms, medical device manufacturers, diagnostics developers, digital health companies, and organizations preparing products for reimbursement and market access benefit from HTA consulting.